ইউরোপীয় ইউনিয়ন - ইংরেজি - EMA (European Medicines Agency)

janssen-cilag international nv - bosentan (as monohydrate) - hypertension, pulmonary; scleroderma, systemic - other antihypertensives - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with world health organization (who) functional class iii. efficacy has been shown in:primary (idiopathic and familial) pah;pah secondary to scleroderma without significant interstitial pulmonary disease;pah associated with congenital systemic-to-pulmonary shunts and eisenmenger’s physiology.some improvements have also been shown in patients with pah who functional class ii.stayveer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital-ulcer disease.

ইউরোপীয় ইউনিয়ন - ইংরেজি - EMA (European Medicines Agency)

viatris limited - tadalafil - hypertension, pulmonary - urologicals - talmanco is indicated in adults for the treatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity. efficacy has been shown in idiopathic pah (ipah) and in pah related to collagen vascular disease.

ইউরোপীয় ইউনিয়ন - ইংরেজি - EMA (European Medicines Agency)

bayer ag - telmisartan, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.pritorplus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.pritorplus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on pritorplus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.

ইউরোপীয় ইউনিয়ন - ইংরেজি - EMA (European Medicines Agency)

novartis europharm ltd - aliskiren, amlodipine - hypertension - agents acting on the renin-angiotensin system - rasilamlo is indicated for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone.

ইউরোপীয় ইউনিয়ন - ইংরেজি - EMA (European Medicines Agency)

noden pharma dac - aliskiren, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension in adults.rasilez hct is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.rasilez hct is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.

ইউরোপীয় ইউনিয়ন - ইংরেজি - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, amlodipine, hydrochlorothiazide - hypertension - cardiovascular system - rasitrio is indicated for the treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently at the same dose level as in the combination.

ইউরোপীয় ইউনিয়ন - ইংরেজি - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension in adults.riprazo hct is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.rirpozo hct is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.

ইউরোপীয় ইউনিয়ন - ইংরেজি - EMA (European Medicines Agency)

pharmathen s.a. - irbesartan - hypertension - agents acting on the renin-angiotensin system - sabervel is indicated in adults for the treatment of essential hypertension.it is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.

ইউরোপীয় ইউনিয়ন - ইংরেজি - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension in adults.sprimeo hct is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.sprimeo hct is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.

ইউরোপীয় ইউনিয়ন - ইংরেজি - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension